Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2025 | 268 | 1.710 |
Why?
|
| Early Detection of Cancer | 13 | 2025 | 529 | 1.050 |
Why?
|
| Multiple Myeloma | 2 | 2014 | 9 | 0.780 |
Why?
|
| Microbiota | 1 | 2022 | 10 | 0.780 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 622 | 0.770 |
Why?
|
| Adenoma | 1 | 2022 | 95 | 0.710 |
Why?
|
| Skin Neoplasms | 3 | 2024 | 58 | 0.590 |
Why?
|
| Humans | 37 | 2025 | 17314 | 0.500 |
Why?
|
| Proteostasis Deficiencies | 1 | 2014 | 1 | 0.440 |
Why?
|
| Amyloidosis | 1 | 2014 | 3 | 0.440 |
Why?
|
| Mass Screening | 5 | 2025 | 672 | 0.370 |
Why?
|
| Male | 17 | 2025 | 9804 | 0.370 |
Why?
|
| Quality Improvement | 2 | 2024 | 188 | 0.350 |
Why?
|
| Immunoglobulin D | 1 | 2010 | 1 | 0.340 |
Why?
|
| Multiple Trauma | 1 | 2010 | 2 | 0.340 |
Why?
|
| Rib Fractures | 1 | 2010 | 2 | 0.340 |
Why?
|
| Neoplasms | 3 | 2022 | 446 | 0.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 12 | 0.320 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 145 | 0.320 |
Why?
|
| Aged | 15 | 2025 | 6084 | 0.320 |
Why?
|
| MicroRNAs | 2 | 2021 | 17 | 0.310 |
Why?
|
| Electronic Health Records | 4 | 2023 | 704 | 0.310 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2021 | 52 | 0.310 |
Why?
|
| Middle Aged | 18 | 2025 | 7836 | 0.300 |
Why?
|
| Female | 19 | 2025 | 12396 | 0.300 |
Why?
|
| Heart Failure | 1 | 2014 | 401 | 0.300 |
Why?
|
| United States | 11 | 2025 | 3866 | 0.250 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2025 | 203 | 0.240 |
Why?
|
| Skin Diseases, Papulosquamous | 1 | 2005 | 1 | 0.230 |
Why?
|
| CD56 Antigen | 1 | 2005 | 1 | 0.230 |
Why?
|
| Killer Cells, Natural | 1 | 2005 | 3 | 0.230 |
Why?
|
| CD4 Antigens | 1 | 2005 | 2 | 0.230 |
Why?
|
| Exanthema | 1 | 2005 | 7 | 0.230 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2005 | 4 | 0.230 |
Why?
|
| Health Services Research | 2 | 2016 | 202 | 0.230 |
Why?
|
| Delivery of Health Care | 5 | 2019 | 390 | 0.220 |
Why?
|
| Occult Blood | 2 | 2022 | 155 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2025 | 149 | 0.210 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 32 | 0.210 |
Why?
|
| Melanoma | 1 | 2024 | 35 | 0.210 |
Why?
|
| Deductibles and Coinsurance | 1 | 2023 | 31 | 0.200 |
Why?
|
| Patient Compliance | 1 | 2025 | 277 | 0.200 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 10 | 0.200 |
Why?
|
| Prepaid Health Plans | 1 | 2022 | 18 | 0.190 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 7 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 53 | 0.190 |
Why?
|
| Adult | 10 | 2024 | 7500 | 0.190 |
Why?
|
| Myxoma | 1 | 2002 | 1 | 0.190 |
Why?
|
| Skin Pigmentation | 1 | 2002 | 6 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2002 | 11 | 0.190 |
Why?
|
| Population Surveillance | 1 | 2024 | 252 | 0.190 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 11 | 0.190 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 18 | 0.190 |
Why?
|
| Feces | 1 | 2022 | 85 | 0.190 |
Why?
|
| Population Dynamics | 1 | 2021 | 6 | 0.180 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 969 | 0.180 |
Why?
|
| Preventive Medicine | 1 | 2021 | 22 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 1925 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 42 | 0.180 |
Why?
|
| Transfusion-Related Acute Lung Injury | 1 | 2021 | 1 | 0.180 |
Why?
|
| Transfusion Reaction | 1 | 2021 | 2 | 0.180 |
Why?
|
| Blood Transfusion | 1 | 2021 | 3 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 16 | 0.170 |
Why?
|
| Cancer Survivors | 1 | 2022 | 101 | 0.170 |
Why?
|
| Colonoscopy | 1 | 2022 | 257 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2025 | 2415 | 0.160 |
Why?
|
| Models, Organizational | 1 | 2019 | 54 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 243 | 0.150 |
Why?
|
| Prospective Studies | 1 | 2022 | 1226 | 0.150 |
Why?
|
| Genetic Testing | 3 | 2014 | 69 | 0.150 |
Why?
|
| Lung | 3 | 2024 | 60 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2022 | 2514 | 0.140 |
Why?
|
| Gene Library | 1 | 2017 | 4 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 5 | 0.130 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 32 | 0.130 |
Why?
|
| ErbB Receptors | 2 | 2016 | 5 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2017 | 24 | 0.130 |
Why?
|
| Serum Albumin | 2 | 2009 | 4 | 0.130 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2016 | 1 | 0.130 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2016 | 1 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 1 | 0.130 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 1 | 2016 | 1 | 0.130 |
Why?
|
| Cell Movement | 1 | 2016 | 5 | 0.130 |
Why?
|
| Uterine Neoplasms | 1 | 2016 | 13 | 0.120 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Strongylida Infections | 1 | 2015 | 1 | 0.120 |
Why?
|
| DNA, Helminth | 1 | 2015 | 1 | 0.120 |
Why?
|
| Meningitis | 1 | 2015 | 3 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2015 | 2 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 10 | 0.120 |
Why?
|
| Smoking | 3 | 2023 | 429 | 0.120 |
Why?
|
| Adolescent | 6 | 2022 | 3538 | 0.120 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2015 | 61 | 0.110 |
Why?
|
| Glomus Jugulare | 1 | 2013 | 1 | 0.110 |
Why?
|
| Glomus Jugulare Tumor | 1 | 2013 | 1 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 338 | 0.110 |
Why?
|
| Research Design | 1 | 2015 | 336 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2013 | 15 | 0.100 |
Why?
|
| Hawaii | 3 | 2022 | 58 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2021 | 1380 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 55 | 0.080 |
Why?
|
| Influenza B virus | 1 | 2010 | 10 | 0.080 |
Why?
|
| Biomarkers | 2 | 2009 | 307 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2010 | 13 | 0.080 |
Why?
|
| Laboratories | 1 | 2010 | 19 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 37 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2009 | 8 | 0.080 |
Why?
|
| Myocardial Infarction | 2 | 2009 | 224 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 17 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 124 | 0.080 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2020 | 16 | 0.080 |
Why?
|
| Child | 3 | 2021 | 2403 | 0.080 |
Why?
|
| Mutation | 3 | 2014 | 132 | 0.070 |
Why?
|
| Incidence | 2 | 2022 | 1266 | 0.070 |
Why?
|
| Health Status Disparities | 2 | 2020 | 149 | 0.070 |
Why?
|
| Myocardial Ischemia | 2 | 2009 | 23 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 2465 | 0.070 |
Why?
|
| Influenza, Human | 1 | 2010 | 282 | 0.060 |
Why?
|
| Data Collection | 2 | 2019 | 238 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 211 | 0.060 |
Why?
|
| Insulinoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 1161 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 310 | 0.060 |
Why?
|
| Recurrence | 1 | 2025 | 165 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2016 | 1160 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 31 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 21 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2023 | 6 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 69 | 0.050 |
Why?
|
| Cobalt | 1 | 2003 | 1 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 7 | 0.050 |
Why?
|
| Neurilemmoma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cushing Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2019 | 1076 | 0.050 |
Why?
|
| Medicare | 1 | 2023 | 192 | 0.050 |
Why?
|
| Prognosis | 2 | 2014 | 603 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2021 | 46 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 32 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 840 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 36 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2022 | 170 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 71 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 86 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 79 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 342 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2019 | 17 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 39 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 460 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 3 | 0.040 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 18 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 8 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 35 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 43 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 304 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 92 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2019 | 29 | 0.040 |
Why?
|
| Research | 1 | 2019 | 61 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 937 | 0.040 |
Why?
|
| Disease Management | 1 | 2019 | 111 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 174 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 605 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 41 | 0.030 |
Why?
|
| Protein Binding | 2 | 2009 | 10 | 0.030 |
Why?
|
| Integrin alpha5 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 45 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 79 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 804 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 89 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 280 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 114 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2013 | 33 | 0.030 |
Why?
|
| Family Health | 1 | 2013 | 45 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 102 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 91 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 99 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 139 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 120 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 58 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 231 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 252 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 535 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2010 | 18 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 27 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 253 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 12 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 879 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 41 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 298 | 0.020 |
Why?
|
| Risk Factors | 1 | 2014 | 3258 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 22 | 0.010 |
Why?
|
| Pancreas | 1 | 2005 | 14 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 2 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 5 | 0.010 |
Why?
|
| ROC Curve | 1 | 2003 | 72 | 0.010 |
Why?
|
Concepts
(199)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(16)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->